Treatment of seventy-eight patients with testicular tumors

• Published in: Nippon Hinyokika Gakkai zasshi Vol. 82; no. 8; p. 1233
• Main Authors: Oyabu, Y, Mihara, T, Yoshitake, N, Ueda, S, Matsuoka, K, Noda, S, Eto, K
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.08.1991
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Combined Modality Therapy; Dysgerminoma - mortality; Dysgerminoma - pathology; Dysgerminoma - therapy; Humans; Male; Orchiectomy; Prognosis; Radiotherapy Dosage; Survival Rate; Testicular Neoplasms - mortality; Testicular Neoplasms - pathology; Testicular Neoplasms - therapy
• ISSN: 0021-5287
• DOI: 10.5980/jpnjurol1989.82.1233

Seventy-eight patients with testicular tumors were treated in our clinic between April, 1972 and October, 1990. The average age of patients with seminoma (37.5 yrs) was higher than that (24.5 yrs) of those with non-seminomatous germ cell tumor (NSGCT). Histopathologically, 34 patients had seminoma and 36 patients had NSGCT. The remaining 8 patients had non-germinal cell tumors. The 5-year survival rate was 76.7%, 90.3% and 75.8% for all patients, seminoma group and NSGCT group, respectively. As for seminoma group, the 5-year survival rate was 100%, 50.0% and 33.3% for Stage I, Stage IIb and Stage III, respectively. The survival rate of Stage IIb and Stage III in seminoma group were lower than Stage I statistically. In NSGCT group, the 5-year survival rate was 100% for Stage I and 26.7% for Stage III, between the two groups there was significant difference. The higher serum LDH and HCG levels, the lower the survival rate in NSGCT. Serum AFP, beta-HCG levels and ESR were unrelated to the survival rate. The survival rate for the patients treated by the chemotherapy including CDDP was compared to those treated by the other therapy in germ cell tumor (greater than or equal to Stage IIb). The survival rate of CDDP group was higher than the others (p less than 0.01).